Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
AIMS: To examine the changes in coronary, all-cause, and cancer mortality in patients with heterozygous familial hypercholesterolaemia (FH) before and after lipid-lowering therapy with statins. METHODS AND RESULTS: A total of 3382 patients (1650 men) aged <80 years were recruited from 21 lipid clinics in the United Kingdom and followed prospectively between 1980 and 2006 for 46 580 person-years. There were 370 deaths, including 190 from coronary heart disease (CHD) and 90 from cancer. The standardized mortality ratio (compared with the population in England and Wales) was calculated before and from 1 January 1992. In patients aged 20-79 years, CHD mortality fell significantly by 37% (95% CI = 7-56) from 3.4- to 2.1-fold excess. Primary prevention resulted in a 48% reduction in CHD mortality from 2.0-fold excess to none, with a smaller reduction of nearly 25% in patients with established disease. Coronary mortality was reduced more in women than in men. In patients without known CHD at registration, all-cause mortality from 1992 was 33% (21-43), lower than in the general population, mainly due to a 37% (21-50) lower risk of fatal cancer. CONCLUSION: The results emphasize the importance of early identification of FH and treatment with statins.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“On the other hand, patients who start attending a lipid clinic before they develop clinical CAD may enjoy a normal life expectancy if well managed.155”
From ESC/EAS Guidelines for the management of dyslipidaemias (2011) · cites this paper as [155]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423 · cited 2×
“LDL-cholesterol concentrations were calculated according to Friedewald et al.(14)”
MethodAntihyperlipidemic and Biochemical Activities of Mcy Protein in Streptozotocin Induced Diabetic Rats
Marella, S., Maddirela, D. R., Badri, K. R., Jyothi Kumar, M. V., & Chippada, A. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000373954 · Cited by 5,938
Swinburn, B., Baba, N. H., Belhadj, M., Deurenberg‐Yap, M., Djazayery, A., Forrester, T., Galuska, D. A., Herman, S. T., James, W. P. T., Kabangu, J. R. M., et al. (2003) · World Health Organization eBooks · Cited by 3,453
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia
Kastelein, J. J. P., Akdim, F., Stroes, E. S. G., Zwinderman, A. H., Bots, M. L., Stalenhoef, A. F. H., Visseren, F. L. J., Sijbrands, E. J. G., Trip, M. D., Stein, E. A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800742 · Cited by 1,241
Lipid screening and cardiovascular health in childhood
Daniels, S. R., Greer, F. R., & and the Committee on Nutrition (2008) · Pediatrics · doi:10.1542/peds.2008-1349 · Cited by 1,178
Smilde, T., van Wissen, S., Awollersheim, H., Trip, M., Kastelein, J., & Stalenhoef, A. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04053-8 · Cited by 918 · cited 1×
“Furthermore, the intensity of statin treatment may have been sub-optimal, since evidence that reducing LDL-C by at least 50% in heterozygous FH prevents the progression of carotid intima medial thickness was not published until 2001.(9) Achieving substantial reductions in LDL was difficult before the introduction of m…”
Background(1991) · BMJ · doi:10.1136/bmj.303.6807.893 · Cited by 815 · cited 5×
“Patients and study design The methods have been described previously.(7) Recruitment to the Simon Broome Register of patients with heterozygous familial hypercholesterolamia began since 1980s.”
BackgroundMethodResultInfluentialRISKS OF ISCHÆMIC HEART-DISEASE IN FAMILIAL HYPERLIPOPROTEINÆMIC STATES
Slack, J. (1969) · The Lancet · doi:10.1016/s0140-6736(69)90930-1 · Cited by 623
Research works printed but not linked: 4
- 1969, 2, 1380
- 1999, Arteriosclerosis, Thrombosis, and Vascular Biology, 142, 105
- 1999, International Journal of Epidemiology, 15, 134
- Sawicka, 1976, Medline Rows With NULL issns Will Point To This, 24, 441
Cited by
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Authors/Task Force Members:, Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, M., Albus, C., Benlian, P., Boysen, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs092 · Cited by 8,490
Authors/Task Force Members, Graham, I., Atar, D., Borch-Johnsen, K., Boysen, G., Burell, G., Cifkova, R., Dallongeville, J., De Backer, G., Ebrahim, S., et al. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm316 · Cited by 3,753
Self-citationESC/EAS Guidelines for the management of dyslipidaemias
Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr158 · Cited by 3,549
Self-citation2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162
Graham (2007) · doi:10.1097/01.hjr.0000277983.23934.c9 · Cited by 1,647
Self-citation
Metadata
- Authors
- Neil, A., Cooper, J., Betteridge, J., Capps, N., McDowell, I., Durrington, P., Seed, M., Humphries, S. E., & on behalf of the Simon Broome Familial Hyperlipidaemia Register Group
- Affiliations
- University of Oxford (GB)
- The Royal Free Hospital (GB)
- Shrewsbury and Telford Hospital NHS Trust (GB)
- University Hospital of Wales (GB)
- University of Manchester (GB)
- University of London (GB)
- Corresponding author
- Neil, A.
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-05-20
- Volume
- 29
- Issue
- 21
- Pages
- 2625-2633
- ISSN
- 0195-668X (ISSN-L)
- 1522-9645
- PMC
- PMC2577142
- OpenAlex
- W2123415255
- Semantic Scholar
- 0d3947c783e67c78ee9e42bb3efb809df66c7b25
- Cited by
- 425
- References
- 41
- Citations by year
- 2026: 6 · 2025: 8 · 2024: 8 · 2023: 17 · 2022: 25 · 2021: 20 · 2020: 19 · 2019: 20 · 2018: 34 · 2017: 25 · 2016: 55 · 2015: 35 · 2014: 37 · 2013: 31 · 2012: 33
- FWCI
- 17.57
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- other-oa
- Locations
- European Heart Journal (publishedVersion, other-oa)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Oxford University Research Archive (ORA) (University of Oxford) (acceptedVersion, cc-by-nc)
- UCL Discovery (University College London) (submittedVersion)
- Research Explorer (The University of Manchester) (submittedVersion)
- Funders
- Pfizer
- British Heart Foundation (PG2005/014, RG/08/008/25291, RG3008)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- heterozygous familial hypercholesterolemia, statins, lipid-lowering therapy, coronary heart disease mortality, all-cause mortality, cancer mortality, primary prevention, sex differences, standardized mortality ratio
- MeSH terms
- Adult, Aged, Coronary Disease, England, Epidemiologic Methods, Female, Humans, Hyperlipoproteinemia Type II, Male, Middle Aged, Neoplasms, Registries, Wales, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study. https://app.cochat.ai/papers/10.1093/eurheartj/ehn422
- The paper
- Neil, A., Cooper, J., Betteridge, J., Capps, N., McDowell, I., Durrington, P., Seed, M., Humphries, S. E., & on behalf of the Simon Broome Familial Hyperlipidaemia Register Group. (2008). Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study. European Heart Journal. https://doi.org/10.1093/eurheartj/ehn422
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.